Tarlatamab 20200469
Research payments
$8,961,774
Through program year 2024, $8,961,774 in research payments was reported against Tarlatamab 20200469, across 48 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $8,679,986 | 24 |
| 2023 | Research | $278,881 | 16 |
| 2022 | Research | $2,907 | 8 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Sally Lau New York, NY Named on 7 payments
- Benjamin Solomon Sioux Falls, SD Named on 6 payments
- Kelly Paulson Edmonds, WA Named on 5 payments
- Missak Haigentz New Brunswick, NJ Named on 5 payments
- Jorge Nieva Los Angeles, CA Named on 5 payments
- Shetal Patel Chapel Hill, NC Named on 4 payments
- Jamal Misleh Newark, DE Named on 4 payments
- Mohammed Almubarak Morgantown, WV Named on 3 payments
- Shirish Gadgeel Detroit, MI Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.